EverSource Wealth Advisors’s Filana Therapeutics FLNA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$377 Hold
425
– – ﹤0.01% 4234
2026
Q2
$506 Sell
425
-2,134
-83% -$3.04K ﹤0.01% 4127
2026
Q1
$4.32K Sell
2,559
-551
-18% -$1.13K ﹤0.01% 3334
2025
Q4
$6.16K Sell
3,110
-659
-17% -$2.11K ﹤0.01% 3035
2025
Q3
$11K Buy
3,769
+1,059
+39% +$2.44K ﹤0.01% 2774
2025
Q2
$4.91K Buy
2,710
+2,213
+445% +$3.94K ﹤0.01% 3167
2025
Q1
$746 Buy
497
+52
+12% +$131 ﹤0.01% 3331
2024
Q4
$1.05K Buy
445
+153
+52% +$2.69K ﹤0.01% 2948
2024
Q3
$8.59K Buy
292
+207
+244% +$4.77K ﹤0.01% 1952
2024
Q2
$1.89K Hold
85
– – ﹤0.01% 2568
2024
Q1
$1.88K Buy
85
+80
+1,600% +$1.84K ﹤0.01% 2408
2023
Q4
$113 Hold
5
– – ﹤0.01% 2593
2023
Q3
$83 Hold
5
– – ﹤0.01% 2458
2023
Q2
$123 Hold
5
– – ﹤0.01% 2438
2023
Q1
$121 Hold
5
– – ﹤0.01% 2329
2022
Q4
$148 Hold
5
– – ﹤0.01% 2266
2022
Q3
$0 Hold
5
– – ﹤0.01% 2110
2022
Q2
$0 Hold
5
– – ﹤0.01% 1865
2022
Q1
$0 Hold
5
– – ﹤0.01% 1826
2021
Q4
$0 Buy
+5
New +$262 ﹤0.01% 1775

Other funds holding FLNA

EverSource Wealth Advisors's FLNA Position: Q3 2026 in Review

EverSource Wealth Advisors held its Filana Therapeutics (FLNA) position steady in Q3 2026 at 425 shares worth $377. The position accounts for ﹤0.01% of the portfolio, ranked #4234.

EverSource Wealth Advisors first reported a position in FLNA in Q4 2021 and has held it in 20 quarters since. The position peaked at $11K in Q3 2025. 28 funds tracked by Wall St. Rank hold FLNA as of Q3 2026.

  • EverSource Wealth Advisors held 425 shares of Filana Therapeutics worth $377 as of Q3 2026.
  • EverSource Wealth Advisors left its Filana Therapeutics share count unchanged in Q3 2026.
  • Filana Therapeutics made up ﹤0.01% of EverSource Wealth Advisors's portfolio in Q3 2026, its #4234 holding.
  • EverSource Wealth Advisors first reported a position in Filana Therapeutics in Q4 2021 and has held it in 20 quarters since.
  • EverSource Wealth Advisors's Filana Therapeutics position peaked at $11K in Q3 2025.
  • 28 funds tracked by Wall St. Rank held Filana Therapeutics as of Q3 2026.

Based on EverSource Wealth Advisors's 13F filing for Q3 2026, filed 4 Nov 2026.